Looking at the 'liste-en-sus' objectives, the most decisive criterion seems to be more stability of the DRG rather than access to innovative medicines; however a higher proportion of the medicines in the 'liste-en-sus' are innovative.
METHODS
The ATIH[2] is a public agency in charge of coding, collecting, analysing, restoring and broadcasting information on hospital activity. Among others, they keep track of all inclusions, delisting and tariff amendment from the 'liste-en-sus' , and the consolidated list is publicly downloadable from their website.
From the latter list, an initial analysis consisted of identifying all the Health Technology Assessments (HTAs) for each product included in the 'liste-en-sus' , those HTAs were downloaded from the HAS website [3] . Then, for each HTA, the following information was collected: assessment date, SMR (medical benefit) and ASMR (improvement in medical benefit) scores. 'innovative' products 'non-innovative' products Medicines which were granted an ASMR IV or V mainly consist in antihaemorrhagics (27%), antianaemics (18%), antineoplastics (15%) and immune sera and immunoglobulins (15%) [4] . Although they are not innovative, those medicines are only used in a proportion of patients and are thus likely to distort DRG. (Figure 3) To put these results into perspective, since 2005, 92% of evaluated medicines were granted an ASMR IV/V: the 'liste-en-sus' medicines are more innovative than the average medicines evaluated [3] . (Figure 4) 
